IL18 and macrophage activation syndrome: Mice with elevated free IL-18 using transgenic IL-18 or IL-18BP KO have no phenotype at baseline, but demonstrate more severe MAS manifestations upon CpG treatment (Fig. 1A, Table 1) [37, 59].